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Abstract TRPC1 and store-operated Ca2? (SOC) entry
have previously been associated with hepatocellular car-
cinoma cell proliferation. The aim of the study was to
determine genes and processes associated with TRPC1
down-regulation and the resulting increase of SOC entry
and decrease in hepatocellular carcinoma cell proliferation.
For this purpose, transcriptome analysis was performed to
determine differentially expressed genes in TRPC1-si-
lenced Huh7 cells. SOC entry- and proliferation-related
genes correlated with TRPC1 down-regulation were also
examined. Changes in SOC entry and cell proliferation
were monitored in the TRPC1-silenced and parental cells
and found to be significantly increased and decreased,
respectively, in TRPC1-silenced cells. A total of 71 genes
were significantly differentially expressed (40 up- and 31
down-regulated), including four mitogen-activated protein
kinase (MAPK) signalling-associated genes. STIM1 levels
were significantly up-regulated and negatively correlated
with TRPC1 levels. In addition, expression of two cell
cycle regulation genes, CDK11A/11B and URGCP, was
observed to decrease, whereas ERBB3 and FGFR4, pro-
survival genes, increased significantly in TRPC1-silenced
cells. In conclusion, these results suggest reciprocal alter-
ations in TRPC1 and STIM1 levels and a role for STIM1 in
the regulation of SOC entry in TRPC1-silenced Huh7 cells.
In addition to TRPC1, STIM1 may participate in Huh7 cell
proliferation by regulating SOC entry. Alterations in
MAPK signalling genes may be involved in diminished
cell proliferation in TRPC1-silenced Huh7 cells. Similarly,
changes in cell cycle regulating genes in TRPC1-silenced
cells indicate possible cell cycle arrest along with com-
pensatory up-regulation of ERBB3 growth factor recep-
tor—amongst others—to maintain hepatocellular
carcinoma cell proliferation.
Keywords Huh7  Hepatocellular carcinoma  Calcium 
Proliferation  Microarray
Introduction
Hepatocellular carcinoma is the most common type of
primary liver cancer and the third leading cause of cancer-
related deaths worldwide, and is associated with poor
prognosis, few effective therapeutic options and resistance
to both chemotherapy and radiotherapy. The Wnt/b-catenin
pathway appears to be commonly deregulated in hepato-
cellular carcinogenesis [1]. Mitogen-activated cascades are
also critical, where inhibition of mitogen-activated protein
kinase (MAPK) and the phosphatidylinositide 3-kinase/
Akt/mammalian target of rapamycin PI3K/Akt/mTOR
pathways have been shown to inhibit tumour growth [2]. A
multi-target kinase inhibitor, sorafenib, that inhibits tumour
angiogenesis and proliferation is currently clinically
available for the treatment of hepatocellular carcinoma [3],
although partial and complete response rates remain rela-
tively low, 30.8 and 2.6 %, respectively [4]. However,
despite sorafenib’s success, effective treatment options are
limited, needing further investigation to identify disrupted
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signalling pathways that may eventually lead to uncon-
trolled proliferation of hepatocellular carcinoma cells.
Transient receptor potential canonical 1 (TRPC1) down-
regulation has previously been shown to be associated with
hepatocellular carcinoma cell proliferation [5], and there-
fore TRPC1 may exist as a potential novel drug target.
TRP channels are a subfamily of the TRP ion channel
superfamily, first discovered in Drosophila melanogaster
composed of approximately 30 members identified in
mammalian cells [6]. The superfamily has been classified
into seven subfamilies: TRPC (canonical), TRPM (melas-
tatin), TRPV (vanilloid), TRPA (ankyrin), TRPP (poly-
cystin), TRPML (mucolipin), and TRPN (NOMPC, no
mechanoreceptor potential C). TRPC1 has been suggested
to be an essential component of store-operated Ca2? (SOC)
entry channel by forming a multimeric complex with other
TRPCs [7]. SOC entry, activated in response to endoplas-
mic reticulum (ER) Ca2? depletion and suggested to be an
ER Ca2? maintenance mechanism, controls a diverse cat-
alogue of cellular functions, including cell cycle regulation
[8].
The mechanism of activation for SOC entry is still
unclear. STIM1, a calcium sensor located in the ER
membrane, has been suggested to link depletion of intra-
cellular Ca2? stores and SOC entry through Orai1 channels
[9]. STIM1 and Orai1-mediated SOC entry is apparent in
vascular smooth muscle proliferation [10], but also plays a
role in hepatocellular carcinoma cell migration and inva-
sion [11]. The interaction between STIM1, Orai1, and
TRPC proteins in mediating SOC entry and their mutual
regulation remains controversial and requires further
investigation. STIM1 was shown to bind TRPC1 and to be
essential for activation and gating TRPC channels [12, 13].
Conversely, TRPC and STIM1/Orai1 signalling have also
been suggested to occur independently in distinct plasma
membrane domains [14].
We have previously observed SOC entry to increase
following TRPC1 silencing, suggesting a negative regula-
tory role of TRPC1 in SOC entry both in vascular smooth
muscle and hepatocellular carcinoma cells [15, 16]. The
potential negative regulatory role of TRPC1 in SOC entry
has recently been reviewed by Dietrich et al. [17]. TRPC6
has also been reported to be up-regulated following TRPC1
silencing in vascular smooth muscle cells [15]. In addition,
Huh7 cell proliferation has been shown to be linked with
TRPC6 and SOC entry, but not with TRPC1 [5]. This
contradicts our own observation that Huh7 cell prolifera-
tion is suppressed in TRPC1-silenced cells without any
alteration to TRPC6 levels [16].
We suggest that these discrepancies may arise from
different compositions of SOC entry channels and regula-
tory mechanisms. Therefore, this study seeks to determine
which genes and pathways become deregulated upon
TRPC1 silencing, to better understand the role of TRPC1 in
SOC entry and hepatocellular carcinoma cell proliferation.
For this purpose, whole-transcriptome gene expression
profiling was performed in TRPC1-silenced Huh7 hepato-
cellular carcinoma cells. We, for the first time, describe
candidate genes related to SOC entry up-regulation and
suppression of proliferation following TRPC1 silencing.
Materials and methods
Cell culture
The well-differentiated human hepatocellular carcinoma
cell line, Huh7 [18], was cultured in DMEM (Biological
Industries) supplemented with 10 % foetal bovine serum
(FBS, Gibco), 2 mM L-glutamine (Gibco), and 0.1 mM
non-essential aminoacid solution (Gibco). Huh7 cells,
originally from Jack Wands Laboratory at Massachusetts
General Hospital, Boston, MA, were a gift provided by
Mehmet Ozturk, DEU University, Turkey. Cells were tes-
ted for authenticity in 2010 and were also regularly
checked for mycoplasma contamination using MycoAlert
Mycoplasma Detection kit (Lonza) in our laboratory.
TRPC1 gene silencing
The silencing sequence (50-GAACAUAAAUUGCGUA-
GAU-30) targeting 361st–379th nucleotides of TRPC1 mRNA
(NM_003304) was cloned into a pSUPERIOR.retro.neo?gfp
vector (Oligoengine). Cells were transfected with 2 lg
silencing vector and an empty vector as a negative control,
using 6 ll FugeneHD transfection reagent (Roche Applied
Science). Transfection efficiency was determined by moni-
toring the GFP signal using fluorescence microscopy (IX71,
Olympus), and cells with efficiency greater than 70 % were
used in further experiments.
Microarray experiments
Total RNA was isolated from TRPC1 silencing vector
(siTRPC1) and empty vector-transfected (control) cells
following 48-h incubation using the instructions provided
in the High Pure RNA Isolation Kit (Roche Applied Sci-
ence). The incubation time was chosen based on our pre-
vious report [16]. 500 ng total RNA was amplified and
biotin labelled using the Illumina Total Prep RNA
Amplification Kit (Ambion). Biotinylated cRNA (750 ng)
was hybridised at 58 C for 16 h to HumanHT-12 v3
expression BeadChip (Direct Hybridization Assay Kit,
Illumina). The BeadChip was washed, blocked, and scan-
ned using (Illumina BeadArray Reader), and Cy3 signal
intensity was measured.
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Data quality was assessed using GenomeStudio, all
system control values were within the expected ranges.
Background fluorescence representing signals from non-
specific dye binding and/or cross-hybridization were sub-
tracted from all other probe intensities using GenomeStu-
dio. R and BioConductor packages were used for analysis.
Following quantile normalisation using lumi, Rank Product
analysis [19] was performed using the RankProd package
to determine differentially expressed genes. Pathway
analysis was performed using DAVID Bioinformatics
Resources 6.7 (functional annotation clustering) [20]. Raw
and processed microarray data have been submitted to
GEO database (GSE77386).
Quantitative real-time RT-PCR and western
blotting
A detailed protocol was described formerly [16]. We pre-
viously showed that following silencing vector transfec-
tion, TRPC1 mRNA levels were reversibly inhibited at
24 h, a significant decrease at 48 h (P B 0.05, n = 4–5),
and recovered at 72 h with significant inhibition in protein
levels at 72 h [16]. Based on this, following 48-h vector
incubation, RNA was isolated using High Pure RNA Iso-
lation Kit (Roche Applied Science). PCR experiments were
performed using FastStart DNA Master SYBR Green I kit
and LightCycler 1.5 (Roche Applied Science). TRPC1
mRNA levels normalised to that of internal 18S rRNA
([TRPC1]/[18S rRNA] 9 1000). The effects of TRPC1
silencing on TRPC1 protein levels were measured by
western blot following 72-h vector incubation as described
previously [16]. Briefly, following separation on 8 % SDS-
PAGE, proteins were transferred to a nitrocellulose mem-
brane using a dry blotting system (iBlot, Invitrogen). Pro-
tein levels were normalised to that of internal b-actin and
represented as relative optical density ([TRPC1]/[b-
actin] 9 1000).
Intracellular calcium measurements
Huh7 cells were grown on 96-well microplates and imag-
ing performed 72 h following silencing vector transfection.
This incubation time was chosen based on our previous
report showing significant changes in TRPC1 protein levels
and SOC entry following 72-h vector incubation [16]. Cells
were incubated for 30 min at room temperature in HEPES-
buffered saline in mM: NaCl 135, KCl 5.9, MgCl2 1.2,
CaCl2 1.5, HEPES 11.6, NaHCO 3 5, glucose 11.5, at pH
7.3 with 1 mg/ml BSA and 2.5 mM fura-2/AM (Molecular
Probes). Cells were then rinsed twice via 15-min incuba-
tions. Changes in intracellular Ca2? levels were monitored
using a microplate reader (Victor3, Perkin Elmer) and
expressed as a ratio based on fluorescence emissions at
510 nm, and monitored sequentially upon excitations at
340 and 380 nm (340/380). The results indicate the average
Ca2? levels in a group of cells, and Ca2? levels in sub-
populations such as transfected and/or viable cells could
not be discriminated in this system. Cyclopiazonic acid
(CPA) at 10 lM concentration that depletes ER-stored
Ca2? was used to activate SOC entry. Cells were exposed
to the Ca2?-free solution, then CPA was applied and, fol-
lowing a transient increase in Ca2? levels due to store
depletion, Ca2? was added to initiate SOC entry. Peak
responses to agents and applications were evaluated due to
time-dependent decays in plateau responses.
Doubling time
Huh7 cells were transfected in 6-well plates and after 72-h
incubation, 1250 cells/well were seeded into E-plate 96.
Cell proliferation was monitored every 30 min for 96 h
using xCELLigence system (Roche Applied Science) that
allows performing real-time and label-free cellular analy-
ses. Changes in proliferation were expressed as cell index
which is defined as (Rn-Rb)/15, where Rb is the back-
ground impedance and Rn is the impedance of the well with
cells. Doubling time was determined with RTCA software
1.2.1 (Roche Applied Science). The time required to reach
a cell index value of 4 from 2 was calculated for each
group.
BrDU incorporation assay
Cell proliferation was also evaluated by measuring
5-bromo-20-deoxyuridine (BrDU) incorporation during
DNA synthesis using colorimetric immunoassay (Cell
Proliferation ELISA, BrdU colorimetric, Roche Applied
Science). Cells (2500 cells/well in a 96-well plate) were
incubated with 10 lM BrdU for 19 h and then fixed for
30 min. Following fixation, cells were incubated with
BrDU antibody conjugated with peroxidase (anti-BrdU-
POD) for 90 min at RT. Then cells were incubated with
substrate (tetramethylbenzidine) for 5 min. Absorbances
(A) at 370 nm and at reference wavelength (490 nm) were
measured and results are expressed as A370–A490).
Negative control signals from cells incubated without anti-
BrDU were subtracted.
Statistical analysis
Data expressed as mean ± standard error of the mean. ‘‘n’’
represents the number of samples used. The significance of
differences was evaluated by using unpaired Student’s
t test for two groups. P B 0.05 was considered significant.
Correlation analysis was performed using Pearson’s cor-
relation coefficients to determine significance. In all cases,
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r C 0.8 was considered evidence of positive correlation,
r B -0.8 of negative correlation. Data analyses and
graphical representation were performed using GraphPad
Prism 5 and RStudio.
Results
Differential gene expression of TRPC1-silenced
Huh7 cells
A total of 71 genes were significantly differentially regu-
lated (40 up; 31 down, Table 1) between TRPC1-silenced
and control cells using Rank Product analysis (FDR, 5 %).
Hierarchical clustering by differentially expressed genes is
shown by heat map (Fig. 1a), where TRPC1-silenced and
control samples distinctly cluster independently of one
another. Functional analysis revealed enrichment for
transporter, catalytic, and nucleic acid binding activities
(Fig. 1b).
MAPK signalling pathway was observed to be signifi-
cantly enriched (enrichment score = 1.02, P = 0.04, fold
enrichment = 4.74, FDR = 27 %). TAO kinase 1
(TAOK1), dual specificity phosphatase 8 (DUSP8),
HSPA6, and HSPA1A genes were clustered in this path-
way. TAOK1 (log2FC = 0.72, P = 4.39E - 06) and
DUSP8 levels (log2FC = 0.61, P = 6.63E - 05) up-reg-
ulated, respectively, whereas heat shock protein genes
HSPA6 and HSPA1A were down-regulated in silenced
cells (log2FC = -0.82, P = 4.18E - 07 and
log2FC = -0.74, P = 2.26E - 06, respectively). Genes
associated with Ca2? entry mechanisms, for example, Ca2?
pumps and exchangers located on ER (SERCA) and plasma
membrane (PMCA and NCX), were not differentially
expressed in TRPC1-diminished cells.
TRPC1 expression was significantly (P B 0.01, n = 5)
decreased in silenced cells (Fig. 2a, b) in both microarray
and subsequent quantitative real-time RT-PCR validation
experiments. TRPC1 expression was strongly correlated
between PCR and microarray in 10 out of 12 samples
(r = 0.83, P B 0.01, n = 10), indicating successful
TRPC1 silencing (Fig. 1c). Samples 9 and 10 (GSE77386)
were excluded in data analysis due to low correlation.
TRPC1 protein levels significantly suppressed by 41 %
(Fig. 1d, P B 0.05, n = 4), demonstrating effective
TRPC1 silencing.
Changes in SOC entry-related genes’ expression
and SOC entry following TRPC1 silencing
We further analysed expression changes in SOC entry-re-
lated genes, including all TRP family members, STIM1,
STIM2, and orai1. TRPA1, TRPC3, C5, C6, C7, TRPN,
TRPM1, M2, M3, M5, M7, M8, TRPML1, ML2, ML3,
TRPP2, P3, P5, TRPV2, V5, V6, orai2, and orai3 failed to
pass the microarray detection threshold as they were not
detectable above the background levels on the microarray.
The heat map illustrates detectable gene expression of TRP
family members, STIM, and orai1 in control and TRPC1-
silenced cells (Fig. 2a).
In contrast to significantly down-regulated TRPC1
levels, STIM1 levels were up-regulated significantly
(P B 0.01, n = 5) without changes in the orai1 levels
following TRPC1 silencing (Fig. 2b). Aside from TRPC1
and STIM1, TRPC1 silencing did not significantly alter
other SOC entry-related genes.
Significant correlations between TRPC1 expression with
TRPM4 and STIM1 were observed (Fig. 2a). TRPM4
levels were positively correlated with that of TRPC1
(r = 0.65, P B 0.05, n = 10) (Fig. 2c), although no sig-
nificant changes in its expression following TRPC1
silencing were observed (n = 5) (Fig. 2b). In addition,
TRPC1 expression was negatively correlated with that of
STIM1 (r = -0.66, P B 0.05, n = 10) (Fig. 2c).
Real-time changes in intracellular Ca2? levels were
monitored after 72 h of vector transfection. In TRPC1-si-
lenced cells, SOC entry induced by CPA enhanced sig-
nificantly (P B 0.05, n = 4) without a change in ER Ca2?
release (Fig. 2d).
Changes in proliferation-related genes’ expression
and Huh7 cell proliferation
Cell proliferation was monitored by using real-time cellular
analysis and doubling time was calculated. Doubling time
increased significantly (P B 0.01, n = 5) indicating sup-
pression of cell proliferation in TRPC1-silenced cells
(Fig. 3a). In addition, BrDU incorporation assay showed a
significant reduction of cell proliferation in TRPC1-silenced
cells compared to control cells (P B 0.05, n = 6, Fig. 3b).
A further analysis was undertaken to consider whether
molecular changes following TRPC1 expression were able
to explain the reduction in cell proliferation. For this pur-
pose, hepatocellular carcinoma cell proliferation-related
genes were selected, and both correlation with TRPC1 and
changes in relative expression were analysed (Fig. 3c–e).
CDK11A/11B and URGCP levels were positively cor-
related with that of TRPC1 (r = 0.82 and r = 0.88,
P B 0.01, n = 10) (Fig. 3e), exhibiting a significant
decrease in expression following TRPC1 silencing
(P B 0.01, n = 5) (Fig. 3c, d). In addition, TRPC1
expression was negatively correlated with that of ERBB3
(r = -0.86, P B 0.01, n = 10) and FGFR4 (r = -0.82,
P B 0.01, n = 10) (Fig. 3e). ERBB3 and FGFR4 levels
were up-regulated significantly following TRPC1 silencing
(P B 0.01, n = 5) (Fig. 3c, d).
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Table 1 The alterations in gene expression levels in TRPC1-silenced Huh7 cells
Gene symbol Description Log2FC FDR P value
1 MARK2 MAP/microtubule affinity-regulating kinase 2 1.02 0.00050 0.000000042
2 ELAVL3 Embryonic lethal, abnormal vision, drosophila-like 3 0.94 0.00020 0.000000042
3 MDM4 Mdm4 p53 binding protein homologue (mouse) 0.89 0.00030 0.000000084
4 CXorf40A Chromosome X open reading frame 40A 0.82 0.0014 0.00000046
5 SNORD13 Small nucleolar RNA, C/D box 13 0.81 0.0022 0.00000092
6 IPO7 Importin 7 0.82 0.0020 0.0000011
7 IPO7P2 N/A (pseudogene) 0.82 0.0020 0.0000011
8 CILP Cartilage intermediate layer protein, nucleotide pyrophosphohydrolase 0.77 0.0030 0.0000020
9 PTHLH Parathyroid hormone-like hormone 0.75 0.0039 0.0000029
10 ACAP3 ArfGAP with coiled-coil, ankyrin repeat and PH domains 3 0.77 0.0039 0.0000033
11 HNRNPKP4 N/A (pseudogene) 0.76 0.0042 0.0000039
12 FXYD5 FXYD domain containing ion transport regulator 5 0.77 0.0041 0.0000041
13 TAOK1 TAO kinase 1 0.72 0.0040 0.0000044
14 KLHL28 Kelch-like 28 (drosophila) 0.73 0.0044 0.0000051
15 HNRNPA3 Heterogeneous nuclear ribonucleoprotein A3 0.73 0.0042 0.0000053
16 SFXN1 Sideroflexin 1 0.71 0.0044 0.0000059
17 TEX28 Testis expressed 28 0.73 0.0046 0.0000066
18 ARL2 ADP-ribosylation factor-like 2 0.71 0.0045 0.0000068
19 MIR4444-2 RNA gene (MicroRNA 4444-2) 0.70 0.0066 0.000010
20 C17orf67 Chromosome 17 open reading frame 67 0.64 0.0082 0.000014
21 RN7SL657P N/A (pseudogene) 0.65 0.013 0.000023
22 ITLN2 Intelectin 2 0.64 0.017 0.000032
23 CXorf40B Chromosome X open reading frame 40B 0.64 0.019 0.000036
24 SPAG8 Sperm-associated antigen 8 0.60 0.020 0.000039
25 SMCP Sperm mitochondria-associated cysteine-rich protein 0.58 0.019 0.000040
26 SLC7A5P1 Solute carrier family 7, member 5 pseudogene 1 0.64 0.019 0.000041
27 COL4A2 Collagen, type IV, alpha 2 0.64 0.021 0.000047
28 DUSP8 Dual specificity phosphatase 8 0.61 0.028 0.000066
29 PRPS2 Phosphoribosyl pyrophosphate synthetase 2 0.58 0.030 0.000072
30 CD1C CD1c molecule 0.55 0.032 0.000080
31 TBX21 T-box 21 0.60 0.032 0.000083
32 INPP5 K Inositol polyphosphate-5-phosphatase K 0.60 0.032 0.000085
33 SUDS3 Suppressor of defective silencing 3 homologue (Saccharomyces cerevisiae) 0.59 0.037 0.00010
34 IPCEF1 Interaction protein for cytohesin exchange factors 1 0.57 0.046 0.00013
35 CLIC5 Chloride intracellular channel 5 0.56 0.048 0.00014
36 SOSTDC1 Sclerostin domain containing 1 0.56 0.048 0.00014
37 DTD2 D-tyrosyl-TRNA deacylase 2 (putative) 0.58 0.047 0.00015
38 MAGEB3 Melanoma antigen family B, 3 0.47 0.047 0.00015
39 LGALS9 Lectin, galactoside-binding, soluble, 9 0.52 0.049 0.00016
40 SLC7A5P2 SLC7A5 pseudogene 0.56 0.050 0.00017
41 ADAMTS8 ADAM metallopeptidase with thrombospondin type 1 motif, 8 -0.97 0.0010 0.000000084
42 HSPA6 Heat shock 70 kDa protein 7 (HSP70B) -0.82 0.0025 0.00000042
43 CES5A Carboxylesterase 5A -0.77 0.0027 0.00000067
44 HERC2P2 N/A (pseudogene) -0.76 0.0038 0.0000014
45 HERC2P9 N/A (pseudogene) -0.76 0.0038 0.0000014
46 HSPA1A Heat shock 70 kDa protein 1A -0.74 0.0045 0.0000023
47 UAP1L1 UDP-N-acteylglucosamine pyrophosphorylase 1-like 1 -0.74 0.0044 0.0000026
48 SCNN1D Sodium channel, non-voltage-gated 1, delta -0.73 0.0043 0.0000029
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Discussion
We have previously described a negative regulatory role
for TRPC1 in SOC entry, both in vascular smooth muscle
and hepatocellular carcinoma cells [15, 16]. These findings
are supported here, where SOC entry was significantly up-
regulated following TRPC1 silencing. In addition, we have
also shown that TRPC6 levels increase in contrast to
TRPC1 down-regulation suggesting a compensatory role
for TRPC6 in SOC entry in vascular smooth muscle cells
[15]. However, it has also been demonstrated that TRPC6
levels remain unaltered by TRPC1 silencing in Huh7 cells
[16]. TRPC6 up-regulation was unable to be replicated in
the present study due to the limitations of the microarray
technology, where TRPC6 was not detectably expressed in
our samples. In addition to TRPC1, TRPM4 was recently
shown to be a negative regulator of SOC entry [21].
Although TRPM4 levels were positively correlated with
down-regulation of TRPC1, TRPM4 expression was not
significantly changed in our study possibly indicating that
they function independently but also potentially due to
tissue-specific variations in SOC entry regulatory mecha-
nisms. In addition, the level of STIM1, another purported
regulator of SOC entry and TRPC1 function [13],
significantly increased suggesting an interplay between
STIM1 and TRPC1 in the elevation of SOC entry. STIM1
has been shown to be critical for the activation and cou-
pling of TRPM4 cation channel with Ca2? stores in myo-
cytes [22]. Based on this, reciprocal up-regulation of
STIM1 suggests a compensatory or contributory role of
STIM1 in the up-regulation of SOC entry in cancer cells.
The changes in protein levels of mentioned channel com-
ponents in SOC entry up-regulated hepatocellular carci-
noma cells need further investigation.
Our previous observations demonstrated that TRPC1
silencing suppresses cell proliferation without affecting
cell migration in Huh7 cells suggesting a regulatory role of
TRPC1 in the proliferation of hepatocellular carcinoma
cells [16]. In contrast to this, Huh7 cell proliferation was
shown to be related with SOC entry and TRPC6 but not
with TRPC1 [5]. In the present study, the doubling time of
TRPC1-silenced Huh7 cells was significantly longer and
cell proliferation measured by BrDU incorporation was
significantly lower than that of control cells, further sup-
porting the anti-proliferative role of TRPC1.
TRPM4 has also been suggested to regulate cell prolif-
eration, where suppression of TRPM4 decreased cervical
cancer cell proliferation via b-catenin degradation [23]. It
Table 1 continued
Gene symbol Description Log2FC FDR P value
49 ANKRD1 Ankyrin repeat domain 1 (cardiac muscle) -0.73 0.0040 0.0000030
50 AMY2B Amylase, alpha 2B (pancreatic) -0.64 0.012 0.0000097
51 AHDC1 AT hook, DNA binding motif, containing 1 -0.67 0.015 0.000014
52 STS Steroid sulfatase (microsomal), isozyme S -0.65 0.017 0.000017
53 C16orf71 Chromosome 16 open reading frame 71 -0.63 0.020 0.000022
54 ZNF354A Zinc finger protein 354A -0.62 0.025 0.000029
55 CCDC93 Coiled-coil domain containing 93 -0.61 0.029 0.000036
56 TRAF1 TNF receptor-associated factor 1 -0.59 0.031 0.000042
57 CEP120 Centrosomal protein 120 kDa -0.62 0.030 0.000042
58 FAM234A Family with sequence similarity 234 member A -0.61 0.032 0.000049
59 GALNT2 Polypeptide N-Acetylgalactosaminyltransferase 2 -0.57 0.041 0.000065
60 SEC24D SEC24 family, member D (S. cerevisiae) -0.58 0.039 0.000066
61 SGTB Small glutamine-rich tetratricopeptide repeat (TPR)-containing, beta -0.51 0.046 0.000081
62 VN1R2 Vomeronasal 1 receptor 2 -0.61 0.044 0.000081
63 LRRN2 Leucine rich repeat neuronal 2 -0.58 0.043 0.000083
64 PSMD4 Proteasome (prosome, macropain) 26S subunit, non-ATPase, 4 -0.38 0.043 0.000086
65 FAM81A Family with sequence similarity 81, member A -0.58 0.045 0.000094
66 SNX10 Sorting nexin 10 -0.55 0.044 0.000095
67 TTTY14 Testis-specific transcript, Y-linked 14 -0.55 0.043 0.000097
68 HKDC1 Hexokinase domain containing 1 -0.56 0.043 0.00010
69 SLC1A7 Solute carrier family 1 (glutamate transporter), member 7 -0.59 0.044 0.00011
70 C4orf3 Chromosome 4 open reading frame 3 -0.57 0.049 0.00012
71 CPSF7 Cleavage and polyadenylation specific factor 7, 59 kDa -0.56 0.048 0.00012
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is well documented that Wnt/b-catenin signalling plays a
key role in the development of hepatocellular carcinoma
[24]. Here, TRPM4 levels were positively correlated with
TRPC1 down-regulation suggesting a possible inhibitory
role for TRPM4 as well as TRPC1 in Huh7 cell prolifer-
ation. Silencing of STIM1 has also been shown to inhibit
hepatocellular carcinoma cell proliferation by cell cycle
arrest [25]. In contrast, we show that cell proliferation is
suppressed in STIM1 up-regulated cells following TRPC1
silencing. Since levels of TRPC1 and SOC entry were not
determined by Wu et al., the discrepancy may result from
varying levels of SOC entry and SOC entry channel
composition. However, we observed alterations in TRPM4
and STIM1 levels in the context of TRPC1 silencing, and
therefore other genes and processes modulated by TRPC1
knockdown may also participate in decreased proliferation.
Fig. 1 The results of differential gene expression analysis. a Heat
map showing the clustering of samples by genes that significantly
increased (red font) or decreased (green font) following TRPC1
silencing. 40 genes were up-regulated and 31 genes down-regulated
significantly in TRPC1-silenced (siTRPC1) cells compared to control
cells. Red and green colours represent relative high and low log2 gene
expression values, respectively. b Molecular functions of differently
expressed genes. c Correlation of TRPC1 expression data obtained
from microarray and quantitative real-time RT-PCR (siTRPC1 =
blue, Pearson correlation, n = 10). d Effects of silencing on TRPC1
protein levels measured by Western blot following 72-h vector
incubation (n = 4). (Color figure online)
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TRPC1 down-regulation along with SOC entry inhibi-
tion can result in reduced cyclin levels, G0/G1 cell cycle
arrest and decreased cell growth in non-small cell lung
carcinoma cell lines [26]. TRPC1 knockdown has previ-
ously been associated with reduced amplitude of SOC
entry and arrest of the endothelial progenitor cell cycle in
G1 phase [27]. In addition, SOC entry was regulated at cell
cycle checkpoints and shown to be at control levels during
G1, up-regulated during S phase whilst suppressed during
mitosis in mast cells [28]. Since we observed SOC entry
up-regulation in a mixed population of cells, further cell
cycle analyses with TRPC1-silenced cells separated into
different cell cycle phases are needed to relate SOC entry
levels with the cell cycle. The present analysis of cell
cycle- and proliferation-associated genes revealed
CDK11A/11B (CDC2L2/L1) down-regulation along with
TRPC1 silencing, suggesting cell cycle arrest. In a recent
study, following CDK11 down-regulation, breast cancer
cells were shown to arrest in G1 phase suggesting a critical
role for CDK11 in proliferation [29]. In our study, mRNA
levels of a further cell cycle-associated gene, up-regulator
of cell proliferation (URGCP/URG4), decreased in parallel
with decreasing cell proliferation suggesting the contribu-
tion of URGCP in Huh7 cell proliferation. URGCP/URG4
Fig. 2 Changes in SOC entry-related genes’ expression and SOC
entry following TRPC1 silencing. a Heat map showing the SOC
entry-related gene expression (log2 values) following TRPC1 silenc-
ing. TRP family members, STIM, and Orai1 proteins with
detectable gene expression were included in the heat map. Red and
green colours represent relative high and low log2 gene expression
values, respectively. b Changes in TRPC1, TRPM4, and STIM1
expression in control and TRPC1-silenced (siTRPC1) cells (n = 5).
c Correlation of TRPC1 expression with TRPM4 and STIM1
(siTRPC1 = blue, Pearson correlation, n = 10). d Cyclopiazonic
acid (CPA)-induced Ca2? elevations and the cumulative data of SOC
entry in control and TRPC1-silenced cells. Changes in endoplasmic
reticulum (ER) Ca2? release and store-operated Ca2? (SOC) entry are
shown (n = 4). Changes in peak responses were evaluated and
expressed as ratio (340/380). (Color figure online)
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is associated with poor prognosis in hepatocellular carci-
noma and its overexpression increased cellular entry into
the G1/S transitional phase in hepatocellular carcinoma
cells [30]. Furthermore, down-regulation of URG4 was
shown to suppress cyclin D1 expression and cell prolifer-
ation in HepG2 hepatocellular carcinoma cells [31], further
supporting our results.
In addition to negative regulators of cell proliferation, a
number of pro-survival genes were up-regulated following
TRPC1 silencing, suggesting a compensatory gene regu-
lation. Growth factor receptor ERBB3 and transforming
growth factor alpha (TGF-a) were recently shown to act as
compensatory survival factors that increased after c-Met
inhibition in hepatocellular carcinoma cells [32]. Up-
regulation of ERBB3 in our study may play a similar
compensatory role in the suppression of TRPC1-silenced
cell proliferation. Furthermore, up-regulation of fibroblast
growth factor receptor 4 (FGFR4) levels, a target for new
small molecule inhibitors for the treatment of hepatocel-
lular carcinoma [33], may also compensate the inhibition
of proliferation.
Based on differential expression analysis, we observed
significant alterations in genes involved in MAPK sig-
nalling which has been associated with hepatocarcinogen-
esis [34]. The levels of TAO kinase 1, which activates p38
MAPK cascades and is a potential therapeutic target for
cancers with defective b-catenin signalling such as hepa-
tocellular carcinoma [24], were significantly up-regulated.
Fig. 3 Changes in cell proliferation- and proliferation-related genes’
expression with that of TRPC1 following silencing in Huh7 cells.
a The cumulative data of doubling time (in hour) in control and
TRPC1-silenced (siTRPC1) cells (n = 5). Real-time changes in cell
proliferation were evaluated and doubling time was calculated. b The
cumulative data of cell proliferation measured by BrDU incorporation
in control and TRPC1-silenced (siTRPC1) cells (n = 6). c Heat map
showing the expression of the proliferation-related genes (CDK11A/
11B, URGCP, ERBB3, and FGFR4) correlated with TRPC1 levels.
Red and green colours represent relative high and low log2 gene
expression values, respectively. d Changes in CDK11A/11B,
URGCP, ERBB3, and FGFR4 expression in control and TRPC1-
silenced cells (n = 5). e Correlation of proliferation-related genes
with TRPC1 expression (siTRPC1 = blue, Pearson correlation,
n = 10). (Color figure online)
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On the other hand, levels of DUSP8, a negative feedback
regulator of MAPKs such as p38, were significantly
increased suggesting deregulation of MAPK signalling
members in the presence of TRPC1-down-regulation.
A putative working model of the genes and pathways
with observed altered expression in TRPC1-silenced Huh7
cells is given in Fig. 4. A limitation of our study is the lack
of protein-level data that would reinforce our findings. In
addition, the validation of the functional roles of the pro-
posed genes in the TRPC1-mediated up-regulation of SOC
entry and suppression of cell proliferation requires further
investigation.
Conclusion
In conclusion, our results show for the first time, the
transcriptome-wide changes in TRPC1-silenced Huh7
cells. Reciprocal alterations in the levels of TRPC1 and
STIM1 have been observed, suggesting their interaction in
regulating SOC entry in Huh7 hepatocellular carcinoma
cells. Decreased TRPC1 may be compensated by increased
expression of STIM1 that possibly takes part in the up-
regulation of SOC entry in TRPC1-silenced hepatocellular
carcinoma cells. Our results further indicate the possible
roles of STIM1 and TRPM4, in addition to TRPC1, in
Huh7 cell proliferation by regulation of SOC entry.
Alterations in MAPK signalling genes may be involved in
diminished cell proliferation in TRPC1-silenced Huh7
cells. Moreover, alterations in cell cycle regulation genes in
TRPC1-diminished cells suggest cell cycle arrest as well as
up-regulation of possible compensatory genes to maintain
cell growth. The data expressed in the current study are
based on microarray expression and may need to be con-
firmed by further studies. The functional link between the
proposed cellular processes and TRPC1 awaits further
investigation.
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